Evidence map›Paper›PMID 41606504›Full record

ArticleBMC infectious diseases2026

Circulating genotypes of human papillomavirus in adult women of reproductive age from the Boeny region of Madagascar: a cross-sectional study to explore needs and opportunities for HPV vaccination in the country.

Ekaterine Garsevanidze, Irina Kislaya, Jean-Marc Kutz, Tahinamandranto Rasamoelina, Sonya Ratefiarisoa, Ravo Razafindrakoto, Zaraniaina Tahiry Rasolojaona, Nantenaina Mathieu Razafindralava, Olivette Totofotsy, Alexina Olivasoa Zafinimampera and 16 more

Abstract read
In one paragraph

Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Ekaterine Garsevanidze *Institute of International Health, Charité Center for Global Health (CCGH), Berlin, Germany.
Irina Kislaya *RG Implementation Research, Bernhard Nocht Institute for Tropical Medicine, Bernhard- Nocht-Str. 74, D-20359, Hamburg, Germany.
Jean-Marc KutzRG Implementation Research, Bernhard Nocht Institute for Tropical Medicine, Bernhard- Nocht-Str. 74, D-20359, Hamburg, Germany.
Tahinamandranto RasamoelinaCentre d'Infectiologie Charles Mérieux, Antananarivo, Madagascar.
Sonya RatefiarisoaUniversity Fianarantsoa, Fianarantsoa, Madagascar.
Ravo RazafindrakotoCentre d'Infectiologie Charles Mérieux, Antananarivo, Madagascar.
Zaraniaina Tahiry RasolojaonaCentre d'Infectiologie Charles Mérieux, Antananarivo, Madagascar.
Nantenaina Mathieu RazafindralavaCentre d'Infectiologie Charles Mérieux, Antananarivo, Madagascar.
Olivette TotofotsyUniversity Fianarantsoa, Fianarantsoa, Madagascar.
Alexina Olivasoa ZafinimamperaUniversity Fianarantsoa, Fianarantsoa, Madagascar.
Tiana RandrianarisoaUniversity Fianarantsoa, Fianarantsoa, Madagascar.
Myriam LassmannRG Implementation Research, Bernhard Nocht Institute for Tropical Medicine, Bernhard- Nocht-Str. 74, D-20359, Hamburg, Germany.
Aaron RemkesRG Implementation Research, Bernhard Nocht Institute for Tropical Medicine, Bernhard- Nocht-Str. 74, D-20359, Hamburg, Germany.
André BritoRG Implementation Research, Bernhard Nocht Institute for Tropical Medicine, Bernhard- Nocht-Str. 74, D-20359, Hamburg, Germany.
Diavolana Koecher AndrianarimananaCentre Hospitalier Universitaire Androva, Mahajanga, Madagascar.
Rivo Solotiana RakotomalalaCentre Hospitalier Universitaire Androva, Mahajanga, Madagascar.
Zoly RakotomalalaUniversity Fianarantsoa, Fianarantsoa, Madagascar.
Pia RauscheRG Implementation Research, Bernhard Nocht Institute for Tropical Medicine, Bernhard- Nocht-Str. 74, D-20359, Hamburg, Germany.
Jana HeyRG Implementation Research, Bernhard Nocht Institute for Tropical Medicine, Bernhard- Nocht-Str. 74, D-20359, Hamburg, Germany.
Sandrine McKay-ChopinInternational Agency for Research on Cancer (IARC), Lyon, France.
Jürgen MayDepartment of Infectious Diseases Epidemiology, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
Monika HamplKöln-Hohenlind Hospital, Cologne, Germany.
Valentina MarcheseRG Implementation Research, Bernhard Nocht Institute for Tropical Medicine, Bernhard- Nocht-Str. 74, D-20359, Hamburg, Germany.
Tarik GheitInternational Agency for Research on Cancer (IARC), Lyon, France.
Rivo Andry RakotoariveloUniversity Fianarantsoa, Fianarantsoa, Madagascar.
Daniela FuscoRG Implementation Research, Bernhard Nocht Institute for Tropical Medicine, Bernhard- Nocht-Str. 74, D-20359, Hamburg, Germany. fusco@bnitm.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHPV is the most common sexually transmitted infection worldwide, related to the vast majority of cervical cancers (CC). Prevention through vaccination against HPV is considered one of the most effective control measures for CC. Madagascar is one of the few countries where HPV vaccination has not yet been widely disstrivuted in the country as the national program just started in December 2025. This study aims to estimate the prevalence of HPV genotypes in rural Madagascar in order to support the planning of a national vaccine implementation strategy.

methodsA cross-sectional study was conducted between 2021 and 2022 in the Boeny region of Madagascar, involving women 18 to 49 years old. Cervico-vaginal lavages were collected and analysed for the presence of HPV DNA, covering 21 HPV genotypes. The prevalence of each HPV genotype was calculated as proportions with 95% confidence intervals (CI95%).

resultsFrom a total of 927 women enrolled, 44.6% (n = 413, CI95%: 41.3, 47.8) tested positive for HPV. The most commonly detected high-risk genotypes were HPV52 8.3% (CI95%: 6.6, 10.3), HPV45 7.2% (CI95%: 5.6, 9.1), and HPV51 4.8% (CI95%: 3.5, 6.3). The prevalence of vaccine-target genotypes was 7.4% (CI95%: 5.8, 9.3), 10.8% (CI95%: 8.9, 13.0), and 29.3% (CI95%: 26.4, 32.4) for 2-valent, 4-valent, and 9-valent vaccines, respectively.

conclusionsOur results suggest that for a vaccination strategy aimed at preventing CC in Boeny, adoption of the 9-valent vaccine would increase the impact of the program. CLINICAL TRIAL: Not applicable.

Indexed as

GenotypeHuman Papillomavirus VirusesPapillomaviridaePapillomavirus InfectionsPapillomavirus VaccinesAdolescentAdultCross-Sectional StudiesDNA, ViralFemaleHumansMadagascarMiddle AgedPrevalenceRural PopulationVaccinationDNA, ViralPapillomavirus VaccinesGenotypesHPVMadagascarPrevalenceVaccination programs

Identifiers

PMID41606504
PMCPMC12924319

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.